Aarti Drugs Limited has announced an interim dividend of ₹2 per share for its shareholders, with the board of directors declaring the dividend at their meeting held on February 3, 2026. The company has set February 9, 2026 as the record date for determining eligible shareholders.

Dividend Declaration Details

The pharmaceutical company's board approved the interim dividend payment of ₹2 per equity share of ₹10 each, representing a 20% dividend for the financial year 2025-26. This dividend distribution demonstrates the company's commitment to returning value to its investor base.

Record Date and Compliance

As per Regulation 42(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Monday, February 9, 2026 has been fixed as the record date for the interim dividend payment. Shareholders holding shares on this date will be eligible to receive the dividend.

The company has informed both BSE Limited and National Stock Exchange of India Limited about this dividend declaration, maintaining compliance with regulatory requirements under Regulation 42(1)(a) and Regulation 43 of SEBI LODR Regulations, 2015.

Shareholder Benefits

The interim dividend announcement provides immediate returns to shareholders without waiting for the annual dividend declaration. This approach allows Aarti Drugs Limited to distribute profits as they are generated, providing regular income streams to investors and reflecting the company's financial stability and cash flow generation capabilities.

Aarti Drugs announced its audited financial results for Q3FY26 ended December 31, 2025, demonstrating robust growth in profitability and revenue expansion across key business segments. The pharmaceutical company's latest quarterly performance reflects strong operational execution and strategic capacity expansion initiatives.

Q3FY26 Financial Performance

The company delivered strong consolidated financial results for the quarter with significant improvement in profitability metrics. Revenue growth was driven by healthy domestic market traction and exceptional performance in the export formulations segment.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, the company demonstrated consistent growth momentum with strong performance across both revenue and profitability parameters.

Segmental Performance Highlights

The company's diversified business portfolio showed mixed performance across segments, with formulations and specialty chemicals leading growth momentum.

Manufacturing Expansion and Operational Updates

According to CFO & COO Adhish Patil, the company successfully operationalized key growth projects during the quarter. The backward integration plant in Sayakha for methyl amines achieved 30% capacity utilization in its first quarter of operations, with plans to reach 50% by March or April 2026. The facility currently fulfills 10-15% of captive Metformin requirements, with expectations to achieve 100% self-reliance within 6-8 months.

The Salicylic Acid plant in Tarapur reached a significant milestone, scaling to above 300 tonnes per month. The downstream Salicylates line implementation is expected to transform this segment into a primary value driver for the company.

Market Performance and Outlook

Standalone business contributed 88% to consolidated revenue, with 63% from domestic market and 37% from exports. Export revenue increased 6% YoY while domestic revenue remained flat. Within the API business, anti-biotic therapeutic category contributed 35.1%, anti-protozoal 19.8%, anti-inflammatory 12.9%, anti-diabetic 16.6%, antifungal 12.2%, and others 3.5% to total API sales.

The formulations segment showed exceptional growth with revenue of ₹76.6 crores in Q3FY26 compared to ₹48.6 crores in Q3FY25, with exports contributing 67% to this revenue.